Table 4.
Associations and performance of the AD-related sncRNA signature with AD incidence
| Analysis model | HR (95% CI) | P valuea | C-statistic | P valueb | ||
|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | ||||
| Model 1 | 0.791 (0.740, 0.842) | |||||
| Model 2 | 3.896 (2.326, 6.524) | < 0.001*** | 0.829 (0.786, 0.872) | < 0.001*** | ||
| Model 3 | 3.043 (2.185, 4.239) | < 0.001*** | 0.849 (0.808, 0.890) | < 0.001*** | ||
| Model 4 | 2.853 (2.020, 4.029) | < 0.001*** | 0.875 (0.840, 0.910) | < 0.001*** | < 0.001*** | < 0.001*** |
Model 1 included age, sex, BMI, APOE ε4, smoking status, education, use of anxiolytic or antidepressants, antihypertensive drugs, statins, and other lipid-lowering medication and MMSE score; Model 2 included ATN status plus the conventional risk factors included in Model 1; Model 3 included the AD-related sncRNA signature plus the conventional risk factors included in Model 2; Model 4 included the AD-related sncRNA signature plus the conventional risk factors included in Model 2 and ATN status. Exposure contrast is per z-score increase in the sncRNA signature. *P value < 0.05, **P value < 0.01, ***P value < 0.001
AD Alzheimer’s disease, HR hazard ratio, BMI Body mass index, MMSE mini-mental state examination.
aP value for the hazard rati
bP value for the likelihood-ratio test